benzonitrile,iodozinc(1+) | 148651-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzonitrile,iodozinc(1+)
• 英文别名: iodo(2-cyanophenyl)zinc
• CAS: 148651-34-7
• 化学式: C₇H₄INZn
• 分子量: 294.41
• InChiKey: YXFDHTIFNYFIOO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  10.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.79
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  benzonitrile,iodozinc(1+) 在 四(三苯基膦)钯 N-氯代丁二酰亚胺 作用下， 以 various solvent(s) 为溶剂， 以85%的产率得到2-(2-氰基苯基)苯甲腈
  参考文献：
  名称：

  Palladium-Catalyzed Synthesis of Biaryls from Arylzinc Compounds UsingN-Chlorosuccinimide or Oxygen as an Oxidant

  摘要：

  在少量 Pd2+ 或 Pd0 催化剂存在下，使用 N-氯代琥珀酰亚胺(NCS)或氧气作为氧化剂，实现了芳基锌化合物的氧化自偶联。根据氧化剂的不同，催化反应涉及不同的反应途径；NCS 或氧气可能分别将 I- 或 Pd0 氧化成 I+ 或 Pd2+。这个反应通过芳基锌中间体，提供了一种从芳基卤化物或芳烃合成联芳基化合物的新型简便方法。

  DOI：

  10.1246/bcsj.74.2415
• 作为产物：
  描述：

  2-碘氰基苯 、 锌 在 水 作用下， 以 further solvent(s) 为溶剂， 以95%的产率得到benzonitrile,iodozinc(1+)
  参考文献：
  名称：

  Ultrasound-Promoted Synthesis of Arylzinc Compounds Using Zinc Powder and Their Application to Palladium(0)-Catalyzed Synthesis of Multifunctional Biaryls

  摘要：

  含有电子吸引基团（如 CO2CH3、CON(CH3)2、CN、Br、Cl 或 CF3）在邻位的芳基锌化合物，通过超声促进的芳基碘化物与锌粉的反应容易制备，随后用于钯(0)催化的交叉偶联反应，与芳基卤化物反应，得到不对称且多功能的双芳基化合物，产率良好。

  DOI：

  10.1246/cl.1993.469

文献信息

• Alpha 1A adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06339090B1

  公开（公告）日：2002-01-15

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  这项发明涉及某些新颖化合物及其衍生物，它们的合成以及它们作为α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织之一是围绕尿道内膜的组织。因此，这些化合物的一个用途是通过减少尿液流动的阻碍，为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。
• Novel Rh(I)-Catalyzed Reaction of Arylzinc Compounds with Methyl Halides
  作者：Kabir M. Hossain、Kentaro Takagi

  DOI：10.1246/cl.1999.1241

  日期：1999.11

  The cross-coupling reactions of arylzinc compounds with methyl iodide or substituted methyl halides like benzyl bromides took place smoothly by the catalysis of Rh(I)-dppf complex.

  芳基锌化合物与甲基碘或苄基溴等取代甲基卤化物的交叉偶联反应在Rh(I)-dppf配合物的催化下顺利进行。
• Nucleophilic Additions of Arylzinc Compounds to Aldehydes Mediated by CrCl₃:  Efficient and Facile Synthesis of Functionalized Benzhydrols, 1(3<i>H</i>)-Isobenzofuranones, Benzyl Alcohols, or Diaryl Ketones
  作者：Yoshihiro Ogawa、Akihiro Saiga、Mitsuo Mori、Takanori Shibata、Kentaro Takagi

  DOI：10.1021/jo991444k

  日期：2000.2.1

  benzhydrols 4a-f in good yields. From arylzinc compounds 1a,b, 3-aryl-1(3H)-isobenzofuranones 3a-f were given by the CrCl(3)-mediated reaction with arylaldehydes 2a-f. Diaryl ketones 5a-e were obtained in good yields by the addition of excess amount of benzaldehyde as an oxidant to the resulting solution after the CrCl(3)-mediated reaction between arylzinc compounds 1c-g and arylaldehydes 2b,g was completed

  在化学计量的CrCl（3）和三甲基氯硅烷（TMSCl）的存在下，芳基锌化合物1c-h向芳基醛2a，b，g的亲核加成反应在室温下平稳进行，以良好的收率得到相应的苯甲醇4a-f。从芳基锌化合物1a，b通过CrCl（3）介导的与芳基醛2a-f的反应得到3-芳基-1（3H）-异苯并呋喃酮3a-f。在芳基锌化合物1c-g与芳基醛2b，g之间完成CrCl（3）介导的反应后，通过向所得溶液中添加过量的苯甲醛作为氧化剂，以高收率获得二芳基酮5a-e。在芳基锌化合物1a，d，f与烷基6b-f的亲核加成中，在添加醛之前，需要用CrCl（3）处理芳基锌化合物，以防止可烯化的醛对芳基锌化合物的快速原型脱锌。在这些CrCl（3）介导的芳基锌化合物与醛的亲核加成反应中，芳基铬（III）可能是反应性中间体。
• CB-1 MODULATING COMPOUNDS AND THEIR USE
  申请人：Olsson Roger

  公开号：US20080090805A1

  公开（公告）日：2008-04-17

  Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or condition that would be alleviated, improved or prevented by administration of a compound that modulates a cannabinoid receptor comprising identifying a subject in need thereof and administering to said subject a therapeutically effective amount of a compound of Formula (I). Also disclosed herein are pharmaceutical compositions comprising a compound of Formula (I).

  本文披露了一种化合物的结构式(I)。同时也披露了使用结构式(I)的化合物调节大麻素受体活性的方法。此外，还披露了一种治疗疾病或症状的方法，该疾病或症状可以通过给予调节大麻素受体的化合物得到缓解、改善或预防，包括确定需要该方法的受试者，并向该受试者施用结构式(I)的化合物的治疗有效量。本文还披露了包含结构式(I)的药物组合物。
• [EN] ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
  申请人：MERCK & CO INC

  公开号：WO2000006565A1

  公开（公告）日：2000-02-10

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  本发明涉及某些新型化合物及其衍生物，它们的合成以及它们作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是治疗良性前列腺增生症。这些化合物在其选择性上具有放松充满α1a受体亚型的平滑肌组织的能力，而不会同时引起低血压。这样的组织可以在尿道内膜周围发现。因此，这些化合物的一个用途是为男性良性前列腺增生症提供急性缓解，从而使尿液流动更加顺畅。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生症的急性和慢性缓解。